Abstract
Vasoactive intestinal peptide (VIP) is a neuropeptide with a broad distribution in the body that exerts very important pleiotropic functions in several systems. The present work reviews the immunology of VIP. Being daring, this neuropeptide could be included in the group of cytokines since it is produced and secreted by different immunocompetent cells in response to various immune signals, plays a broad spectrum of immunological functions, and exerts them, in a paracrine and/orautocrine way, through three different specific receptors. Although VIP has been classically considered as an immunodepressant agent, and its main described role has been as an anti-inflammatory factor, several evidences suggest that a better way to see this peptide is as a modulator of the homeostasis of the immune system. In the last decade, the pharmacology of VIP has spectacularly grown, and VIP itself, as well as more stable VIP-derived agents, have been used or proposed as efficient therapeutical treatments of several disorders, specially inflammatory and autoimmune diseases, such as septic shock, rheumatoid arthritis, multiple sclerosis, Crohns disease and autoimmune diabetes. A broad field of perspectives is actually open, and further investigations will help us to definitively understand the immunology of this “very important peptide”
Current Pharmaceutical Design
Title: Immunology of VIP: A Review and Therapeutical Perspectives
Volume: 7 Issue: 2
Author(s): R.P. Gomariz, C. Martinez, C. Abad, J. Leceta and M. Delgado
Affiliation:
Abstract: Vasoactive intestinal peptide (VIP) is a neuropeptide with a broad distribution in the body that exerts very important pleiotropic functions in several systems. The present work reviews the immunology of VIP. Being daring, this neuropeptide could be included in the group of cytokines since it is produced and secreted by different immunocompetent cells in response to various immune signals, plays a broad spectrum of immunological functions, and exerts them, in a paracrine and/orautocrine way, through three different specific receptors. Although VIP has been classically considered as an immunodepressant agent, and its main described role has been as an anti-inflammatory factor, several evidences suggest that a better way to see this peptide is as a modulator of the homeostasis of the immune system. In the last decade, the pharmacology of VIP has spectacularly grown, and VIP itself, as well as more stable VIP-derived agents, have been used or proposed as efficient therapeutical treatments of several disorders, specially inflammatory and autoimmune diseases, such as septic shock, rheumatoid arthritis, multiple sclerosis, Crohns disease and autoimmune diabetes. A broad field of perspectives is actually open, and further investigations will help us to definitively understand the immunology of this “very important peptide”
Export Options
About this article
Cite this article as:
R.P. Gomariz , C. Martinez , C. Abad , J. Leceta and M. Delgado , Immunology of VIP: A Review and Therapeutical Perspectives, Current Pharmaceutical Design 2001; 7 (2) . https://dx.doi.org/10.2174/1381612013398374
DOI https://dx.doi.org/10.2174/1381612013398374 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
p38 Mitogen-Activated Protein Kinase (MAPK) in Rheumatoid Arthritis
Mini-Reviews in Medicinal Chemistry JAK3 Inhibitors in Organ Transplantation and Autoimmune Disease
Recent Patents on Inflammation & Allergy Drug Discovery G Protein β γ Subunits as Targets for Small Molecule Therapeutic Development
Combinatorial Chemistry & High Throughput Screening Modulation of Matrix Metalloproteinase Activity by Tobacco Cigarette Smoke
Current Chemical Biology Role of Renin-Angiotensin System in Inflammation, Immunity and Aging
Current Pharmaceutical Design Contribution of Dietary Factors to Peroxisome Proliferator-Activated Receptor-Mediated Inflammatory Signaling in Arthritic Diseases
Current Rheumatology Reviews Effect of Different Carriers on In Vitro and In Vivo Drug Release Behavior of Aceclofenac Proniosomes
Current Drug Delivery Immune Deviation Strategies in the Therapy of Psoriasis
Current Drug Targets - Inflammation & Allergy Novel Biomarkers for Lupus Nephritis in the “OMICS” Era
Current Medicinal Chemistry Desensitization for Drug Hypersensitivity to Chemotherapy and Monoclonal Antibodies
Current Pharmaceutical Design Bone Degeneration, Inflammation and Secondary Complications of Arthritis: Potential Targets and their Natural Inhibitors
Mini-Reviews in Medicinal Chemistry 1, 3, 6-Trihydroxy-7-Methyl-9, 10-Anthracenedione Isolated from genus Lindera with Anti-Cancer Activity
Anti-Cancer Agents in Medicinal Chemistry Therapeutic Approaches for the Management of Autoimmune Disorders via Gene Therapy: Prospects, Challenges and Opportunities
Current Gene Therapy Chloroquine: An Old Drug with New Perspective Against Giardiasis
Recent Patents on Anti-Infective Drug Discovery Pharmacophore-Based Discovery of New Human Dihydroorotate Dehydrogenase Inhibitor
Medicinal Chemistry Molecular Players at the Intersection of Obesity and Osteoarthritis
Current Drug Targets Interleukin-26, An Epitheliotropic T-Cell Cytokine
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Chemokines in Rheumatic Diseases
Current Drug Targets Feasibility and Prospects for Anti-Inflammatory Antibodies in the Treatment and Disease Management of Influenza
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Neuropathic Pain: Is the End of Suffering Starting in the Gene Therapy?
Current Drug Targets